First, although we found that lower SLC7A2 expression was associated with worse prognosis of NSCLC, and its deficiency aggravated chemoresistance, we did not determine whether and how SLC7A2 could modulate the influx transporter of multiple anti-tumor drugs. The gene discussed is SLC7A2; the disease is neoplasm.